|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.60 - 2.80|
|52 Week Range||1.50 - 3.60|
|PE Ratio (TTM)||100.00|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
RALEIGH, N.C. , Sept. 19, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo , Vice Chairman, President and Chief Executive Officer, will present ...
RALEIGH, N.C., Sept. 12, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) announced today that Health Canada has granted market authorization to formally transfer the Drug Identification Number (DIN) ownership of BELBUCA® (buprenorphine) buccal film in Canada to BDSI's commercial partner, Purdue Pharma (Canada). As previously announced, this approval triggers a milestone payment to BDSI. BELBUCA incorporates BDSI's BioErodible MucoAdhesive (BEMA®) drug delivery technology and is the first and only long-acting opioid that uses novel buccal film technology to deliver buprenorphine for appropriate patients living with chronic pain.
RALEIGH, N.C., Sept. 7, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) presented three posters including results from an analysis of data which evaluated the reported adverse respiratory effects of BELBUCA® (buprenorphine) buccal film and a separate analysis of potential health economic benefits of buprenorphine at the PAINWeek 2017 Conference being held this week in Las Vegas, NV. Results from a retrospective and systematic review of the adverse event data from 16 clinical trials (total of 2458 subjects) that comprised the BELBUCA New Drug Application (NDA) as well as post-marketing data (from FDA approval in October 2015 through time of analysis in July 2017) were consistent with the ceiling effect of buprenorphine on respiratory depression that has been described in scientific literature.